Central nervous system cancers, version 2, J Natl Compr Canc Netw, vol.12, pp.1517-1523, 2014. ,
Immunomodulatory effects of radiation: what is next for cancer therapy?, Future Oncol, vol.12, pp.239-256, 2016. ,
Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases, J Neurooncol, vol.125, pp.149-156, 2015. ,
In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase, Clin Cancer Res, vol.15, pp.3050-3057, 2009. ,
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032, Radiother Oncol, vol.98, pp.394-399, 2011. ,
Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma, J Clin Oncol, vol.31, pp.283-287, 2013. ,
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy, J Clin Oncol, vol.32, pp.54-56, 2014. ,
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients, Ann Oncol, vol.26, pp.1238-1244, 2015. ,
Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia, Strahlenther Onkol, vol.190, pp.1080-1081, 2014. ,
Severe radiotherapy-induced extracutaneous toxicity under vemurafenib, Eur J Dermatol, vol.23, pp.879-881, 2013. ,
Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?, Eur J Dermatol, vol.23, pp.544-545, 2013. ,
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy, J Clin Oncol, vol.31, pp.220-222, 2013. ,
Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib, Strahlenther Onkol, vol.190, pp.229-232, 2014. ,
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib, Melanoma Res, vol.24, pp.512-516, 2014. ,
Vemurafenib and radiation therapy in melanoma brain metastases, J Neurooncol, vol.113, pp.411-416, 2013. ,
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity, J Clin Oncol, vol.31, pp.3844-3845, 2013. ,
LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases, J Neurooncol, vol.122, pp.121-126, 2015. ,
Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib, Melanoma Res, vol.24, pp.172-176, 2014. ,
BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis, Melanoma Res, vol.26, pp.387-394, 2016. ,
On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases, Ann Oncol, vol.25, pp.2086-2091, 2014. ,
BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases, J Neurosurg, vol.126, pp.726-734, 2017. ,
Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment, J Neurosurg, vol.123, pp.395-401, 2015. ,
Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases, J Neurooncol, vol.127, pp.607-615, 2016. ,
Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases, Melanoma Res, vol.26, pp.382-386, 2016. ,
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas, Clin Cancer Res, vol.5, pp.2884-2890, 1999. ,
Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death, Mol Biol Cell, vol.10, pp.2493-2506, 1999. ,
Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation, Oncogene, vol.15, pp.1191-1197, 1997. ,
Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure, Asian Pac J Cancer Prev, vol.14, pp.5699-5703, 2013. ,
A phase II study of icotinib and wholebrain radiotherapy in Chinese patients with brain metastases from nonsmall cell lung cancer, Cancer Chemother Pharmacol, vol.76, pp.517-523, 2015. ,
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer, Lung Cancer, vol.59, pp.407-410, 2008. ,
Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer, J Korean Neurosurg Soc, vol.58, pp.205-210, 2015. ,
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases, J Natl Cancer Inst, vol.106, 2014. ,
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from nonsmall-cell lung cancer, Int J Radiat Oncol Biol Phys, vol.74, pp.1391-1396, 2009. ,
Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis, Onco Targets Ther, vol.9, pp.1135-1143, 2016. ,
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population, Lung Cancer, vol.65, pp.198-203, 2009. ,
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis, Lung Cancer, vol.70, pp.174-179, 2010. ,
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03), Eur J Cancer, vol.48, pp.377-384, 2012. ,
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320, Int J Radiat Oncol Biol Phys, vol.85, pp.1312-1318, 2013. ,
Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from nonsmall cell lung cancer, Cell Biochem Biophys, vol.71, pp.1261-1265, 2015. ,
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer, J Clin Oncol, vol.31, pp.895-902, 2013. ,
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from nonsmall-cell lung cancer: a retrospective study, Asian Pac J Cancer Prev, vol.13, pp.909-914, 2012. ,
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy, Oncotarget, vol.6, pp.8366-8376, 2015. ,
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma, Drug Des Devel Ther, vol.7, pp.1179-1186, 2013. ,
Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer, Radiat Oncol, vol.9, p.117, 2014. ,
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study, Lung Cancer, vol.96, pp.93-100, 2016. ,
Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis, Cancer Med, vol.5, pp.1055-1065, 2016. ,
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases, Oncotarget, vol.6, pp.16725-16734, 2015. ,
Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC), Oncotarget, vol.8, pp.13304-13311, 2017. ,
Distinct expression of various angiogenesis factors in mice brain after whole-brain irradiation by X-ray, Neurochem Res, vol.42, pp.625-633, 2017. ,
Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis, PLoS One, vol.5, p.11222, 2010. ,
Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells, Cancer Res, vol.64, pp.5398-5406, 2004. ,
Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: The University of Rochester Experience, Am J Clin Oncol, 2015. ,
The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery, J Neurosurg, vol.116, pp.978-983, 2012. ,
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma, BJU Int, vol.108, pp.673-678, 2011. ,
Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer, Urol Oncol, vol.30, issue.3, p.290, 2012. ,
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma, Am J Clin Oncol, vol.36, pp.620-624, 2013. ,
Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report, Anticancer Drugs, vol.27, pp.427-432, 2016. ,
A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies, Cancer, vol.117, pp.5548-5559, 2011. ,
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases, Cancer Cell, vol.6, pp.553-563, 2004. ,
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization, Clin Cancer Res, vol.13, pp.3395-3402, 2007. ,
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, Blood, vol.98, pp.1904-1913, 2001. ,
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery, PLoS One, vol.5, 2010. ,
Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials, Mol Clin Oncol, vol.4, pp.833-838, 2016. ,
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio, Neuro Oncol, vol.18, pp.1313-1318, 2016. ,
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours, Ann Oncol, vol.25, pp.2351-2356, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02939568
Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients, Int J Radiat Oncol Biol Phys, vol.81, pp.631-636, 2011. ,
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs, vol.18, pp.23-28, 2007. ,
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases, Breast Cancer Res Treat, vol.142, pp.405-414, 2013. ,
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer, J Neurooncol, vol.112, pp.199-207, 2013. ,
Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature, Ecancermedicalscience, vol.9, p.586, 2015. ,
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases, Breast Cancer Res Treat, vol.157, pp.307-318, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02296735
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema, Neuro Oncol, vol.16, pp.1006-1009, 2014. ,
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer, J Neurooncol, vol.131, pp.69-72, 2017. ,
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases, BMC Cancer, vol.16, p.391, 2016. ,
Radiation and immune checkpoint blockade: from bench to clinic, Semin Radiat Oncol, vol.27, pp.289-298, 2017. ,
Fractionated but not singledose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res, vol.15, pp.5379-5388, 2009. ,
Combining radiotherapy and cancer immunotherapy: a paradigm shift, J Natl Cancer Inst, vol.105, pp.256-265, 2013. ,
Radiation and immunotherapy: a synergistic combination, J Clin Invest, vol.123, pp.2756-2763, 2013. ,
Combinations of immunotherapy and radiation in cancer therapy, Front Oncol, vol.4, p.325, 2014. ,
Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?, Ann Oncol, vol.27, pp.371-372, 2016. ,
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies, Eur J Cancer, vol.48, pp.3045-3051, 2012. ,
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment, Int J Radiat Oncol Biol Phys, vol.92, pp.368-375, 2015. ,
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival, J Neurosurg, vol.117, pp.227-233, 2012. ,
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery, Melanoma Res, vol.23, pp.191-195, 2013. ,
Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases, Am J Clin Oncol, 2015. ,
Ipilimumab and radiation therapy for melanoma brain metastases, Cancer Med, vol.2, pp.899-906, 2013. ,
Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery, Cancer Med, vol.4, pp.1-6, 2015. ,
Ipilimumab and whole brain radiation therapy for melanoma brain metastases, J Neurooncol, vol.121, pp.159-165, 2015. ,
The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab, J Neurosurg, vol.127, pp.1007-1014, 2017. ,
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol, vol.27, pp.434-441, 2016. ,
Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases, Cancer Immunol Res, vol.4, pp.481-487, 2016. ,
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery, Cancer, vol.122, pp.3051-3058, 2016. ,
Response assessment criteria for brain metastases: proposal from the RANO group, Lancet Oncol, vol.16, pp.270-278, 2015. ,